8-K

                            UNITED STATES
                 SECURITIES AND EXCHANGE COMMISSION
                       Washington, D. C. 20549

                              FORM 8-K

                           CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 15, 2003

                         HEMACARE CORPORATION
         (Exact Name of Registrant as Specified in its Charter)

                              CALIFORNIA
            (State or other jurisdiction of incorporation)

     000-15223                                95-3280412
(Commission File No.)             (IRS Employer Identification No.)

                       21101 Oxnard Street
                     Woodland Hills, CA 91367
         (Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (818) 226-1968




ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number	  Description
- --------------    -----------------------------------------------

99.1	          Press Release issued by HemaCare, dated
                  September 15, 2003


Item 9.   REGULATION FD DISCLOSURE

On September 15, 2003, HemaCare Corporation issued a press release
announcing the closure of some of its blood management programs in
order to achieve sustained profitability. A copy is attached as
Exhibit 99.1 to this report and is
incorporated herein by reference.

The information in this Current Report on Form 8-K, including
the exhibits, will not be treated as "filed" for the purposes of
Section 18 of the Securities and Exchange Act of 1934 (the
"Exchange  Act") or otherwise subject to the liabilities of that
section.  This information will not be incorporated by reference
into a filing under the Securities Act of 1933, or into another
filing under the Exchange Act, unless that filing expressly
refers to specific information in this report.

                            SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.


Date: September 15, 2003	    HEMACARE CORPORATION

                                    /s/ Judi Irving
                                    -------------------------
				    Judi Irving,
                                    Chief Executive Officer



                         EXHIBIT INDEX

Exhibit Number   Description
- --------------   -----------------------------------------------
99.1		 Press Release issued by HemaCare, dated
                 September 15, 2003

EX-99

                            [LOGO]


                    N E W S   R E L E A S E

For Immediate Release

Contact:  HemaCare Corporation
          JoAnn Mannise, Director of Investor Relations
          Phone: 877-310-0717
          Email: www.hemacare.com

            HEMACARE CORPORATION ANNOUNCES CLOSURE
                  OF BLOOD MANAGEMENT PROGRAMS


       Los Angeles, CA, September 15, 2003 - - HemaCare Corporation
announced today a restructuring intended to achieve sustained
profitability.  After a comprehensive review and analysis of operations,
the Company will close several of its blood management programs outside of
California, streamline business processes and realign reporting
relationships.

        Closure of programs in Albany, NY and Williston, VT will occur in
September and others will be terminated before year-end.

       President and Chief Executive Officer, Judi Irving, commented, "These
actions are the result of a comprehensive evaluation of HemaCare's
operations that was initiated upon my appointment as CEO in December 2002.
As announced earlier, we are committed to achieving an operating profile
consistent with sustained profitability and believe these steps are
necessary to realize this objective. Every aspect of the business is
subject to fine-tuning to achieve profitability.  Restructuring benefits
are expected to include improving total operating margins for the remaining
blood management programs."

       HemaCare is in the process of determining the costs associated with
the restructuring and discontinuation of these programs. These costs will
be reported in the third and fourth quarter of 2003.

                        ABOUT HEMACARE CORPORATION

	Founded in 1978, HemaCare is a national provider of blood products
and services and the only publicly traded company engaged in the blood
services industry in the U.S.  HemaCare is licensed by the FDA and
accredited by the American Association of Blood Banks.  The Company focuses
on providing cost effective, high quality solutions to the blood-related
needs of U.S. hospitals.

                                    -more -


This press release contains "forward-looking statements" within the meaning
of the term in the Private Securities Litigation Reform Act of 1995 (Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including the Company's
expectation as to the timing and effect of the proposed restructuring and
the likelihood of achieving sustained profitability.  Additional written or
oral forward-looking statements may be made by the Company from time to
time in filings with the Securities and Exchange Commission or otherwise.
Statements contained herein that are not historical facts are forward-
looking statements pursuant to the safe harbor provisions referenced above.
Forward-looking statements are inherently subject to risks and
uncertainties some of which cannot be predicted or quantified.  Such
risks and uncertainties include, without limitation, the risks and
uncertainties set forth from time to time in reports filed by the Company
with the Securities and Exchange Commission.  Although the Company
believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such
expectations will prove to have been correct.  Consequently, future events
and actual results could differ materially from those set forth in,
contemplated by, or underlined in the forward-looking statements
contained herein.  The Company undertakes no obligation to publicly
release any revision to these forward-looking statements made to
reflect events or circumstances after the date hereof.

                                     ###